CAJ | 학술논문

目的探讨依达拉奉减轻大鼠小体积肝移植物缺血再灌注损伤的作用及其可能机制.方法采用成年雄性SD大鼠作为肝移植的供、受者,随机将受者分为依达拉奉组和对照组,每组8只.依达拉奉组受者移植前30 min经阴茎背静脉注射依达拉奉3 mg/kg,对照组受者仅给予等量生理盐水.采用改良的二袖套法建立大鼠40%(供肝重量与受者全肝重量比)小体积供肝肝移植模型.术后6 h时,处死两组受者,使用全自动生化分析仪检测血清天冬氨酸转氨酶(AST)和丙氨酸转氨酶(ALT)水平,采用酶联免疫吸附试验(ELISA)法检测移植肝组织中肿瘤坏死因子α(TNF-α)含量,使用相应的检测试剂盒检测移植肝组织中MDA含量以及SOD和MPO的活性.同时,取移植肝组织进行病理学检测,观察肝组织病理损伤情况.结果术后6h,依达拉奉组受者血清AST和ALT水平分别为(825.50±72.87)U/L和(687.40±72.21)U/L,对照组分别为(1188.03±124.04)U/L和(988.66±91.07)U/L,依达拉奉组明显低于对照组,两组间比较,差异均有统计学意义(P<0.01).与对照组比较,依达拉奉组受者移植肝组织中MDA和TNF-α含量明显下降,MPO活性也明显下降,而SOD活性则明显增加,两组间比较,差异均有统计学意义(P<0.01).移植肝组织病理学检查发现,对照组肝细胞发生明显的空泡样变性伴局部坏死灶,肝小叶结构破坏,门脉周围水肿、充血,炎症细胞浸润明显;依达拉奉组肝损伤明显减轻,小叶结构保存完整,肝细胞变性、坏死轻微,炎症细胞浸润明显减少.结论依达拉奉能够明显减轻大鼠小体积肝移植物缺血再灌注损伤,其机制可能与增强抗氧化能力、抑制脂质过氧化以及减轻炎症反应密切相关.
목적 탐토의체랍봉감경대서소체적간이식물결혈재관주손상적작용급기가능궤제.방법 채용성년웅성SD대서작위간이식적공、수자,수궤장수자분위의체랍봉조화대조조,매조8지.의체랍봉조수자이식전30 min경음경배정맥주사의체랍봉3 mg/kg,대조조수자부급여등량생리염수.채용개량적이수투법건립대서40%(공간중량여수자전간중량비)소체적공간간이식모형.술후6 h시,처사량조수자,사용전자동생화분석의검측혈청천동안산전안매(AST)화병안산전안매(ALT)수평,채용매련면역흡부시험(ELISA)법검측이식간조직중종류배사인자α(TNF-α)함량,사용상응적검측시제합검측이식간조직중MDA함량이급SOD화MPO적활성.동시,취이식간조직진행병이학검측,관찰간조직병리손상정황.결과 술후6h,의체랍봉조수자혈청AST화ALT수평분별위(825.50±72.87)U/L화(687.40±72.21)U/L,대조조분별위(1188.03±124.04)U/L화(988.66±91.07)U/L,의체랍봉조명현저우대조조,량조간비교,차이균유통계학의의(P<0.01).여대조조비교,의체랍봉조수자이식간조직중MDA화TNF-α함량명현하강,MPO활성야명현하강,이SOD활성칙명현증가,량조간비교,차이균유통계학의의(P<0.01).이식간조직병이학검사발현,대조조간세포발생명현적공포양변성반국부배사조,간소협결구파배,문맥주위수종、충혈,염증세포침윤명현;의체랍봉조간손상명현감경,소협결구보존완정,간세포변성、배사경미,염증세포침윤명현감소.결론 의체랍봉능구명현감경대서소체적간이식물결혈재관주손상,기궤제가능여증강항양화능력、억제지질과양화이급감경염증반응밀절상관.
Objective To investigate the protective effect of edaravone against ischemiareperfusion injury in small-for-size rat liver grafts and its possible mechanisms. Methods 40 % small-for-size rat liver transplantation model was established by using modified two-cuff technique, adult male SD rats were used as donors and recipients, and 16 recipient rats were randomly divided into two groups (8 cases in each group), saline control group (control group) and edaravone treatment group (ED group). In the ED group, 3 mg/kg edaravone was given intravenously via penile vein 30 min before transplantation in the recipients. The same amount of saline was given in the control group at the same time points. Serum hepatic function (AST and ALT) and histopathological changes were analyzed; the contents of MDA and SOD, and hepatic myeloperoxidase (MPO) activity in liver grafts after 6 h were determined; and TNF-α levels at 6th h after reperfusion were measured by using enzyme-linked immunosorbent assay (ELISA method). Results As compared with control group,serum AST and ALT levels were significantly reduced at the 6th h after reperfusion in ED group (AST: 825. 50 5±72. 87 vs 1188. 03 ± 124. 04; ALT. 687. 40 5±72. 21 vs 988. 66 ± 91.07, P<0. 01 ).The content of MDA was lower and SOD level was higher in ED group significantly than in control group (P<0. 01). As compared with control group, hepatic TNF-α levels and MPO activity at the 6th h after reperfusion were significantly decreased in ED group (P<0. 01 ). Histopathological analysis revealed disruption of lobular architecture, apparent hepatocelluar degeneration accompanied by focal necrosis, significant edema, congestion and inflammatory cell infiltration in periportal area at the 6th h after reperfusion in control group, but minimal liver damage was observed in ED group. Conclusion Edaravone could ameliorate early ischemia-reperfusion injury in small-for-size liver grafts significantly.The protective mechanisms were mediated in part by increasing antioxidant ability, inhibiting lipid peroxidation, and down-regulating inflammatory reaction.